The divergent requirement for tolerance to support conception and protective response against sexually transmitted infections defines the unique immunological dynamics in the female reproductive tract (FRT). In part, these requirements are achieved by the cyclic modulation of cytolytic CD8T cell function in the FRT that underlie the respective immunosuppressive and immunocompetent milieus during the secretory and proliferative phases of the menstrual cycle. The CD8T cell function can be dampened by exposure to indoleamine 2,3-dioxygenase and/or arginase enzymes. Indeed, these 2 enzymes are known as primary inducers of immune suppression in tumor microenvironments. This review discusses the intriguing parallel expression of these 2 enzymes in tumor microenvironments and in the secretory endometrium. We surmise that investigating the underlying natural mechanisms that suppress and restore the immunocompetence of CD8T cells in the FRT each month may provide valuable insights into ways to artificially recapitulate these mechanisms and inhibit immune suppression in tumor microenvironments.
HoltanSGCreedonDJHaluskaPMarkovicSN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Paper presented at: Mayo Clinic Proceedings, November 2009.
2.
BoonTvan der BruggenP. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183(3):725–729.
3.
MellorALMunnDH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–774.
4.
MunnDHZhouMAttwoodJT. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281(5380):1191–1193.
5.
KungJTBrooksSBJakwayJPLeonardLLTalmageDW. Suppression of in vitro cytotoxic response by macrophages due to induced arginase. J Exp Med. 1977;146(3):665–672.
6.
NagaevaOJonssonLMincheva-NilssonL. Dominant IL-10 and TGF-beta mRNA expression in gammadeltaT cells of human early pregnancy decidua suggests immunoregulatory potential. Am J Reprod Immunol. 2002;48(1):9–17.
7.
LinHMosmannTRGuilbertLTuntipopipatSWegmannTG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol. 1993;151(9):4562–4573.
8.
MorisakiTKatanoMIkuboA. Immunosuppressive cytokines (IL-10, TGF-beta) genes expression in human gastric carcinoma tissues. J Surg Oncol. 1996;63(4):234–239.
9.
ToutiraisOChartierPDuboisD. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw. 2003;14(4):246–255.
10.
HeikkinenJMottonenMAlanenALassilaO. Phenotypic characterization of regulatory T cells in the human decidua. Clin Exp Immunol. 2004;136(2):373–378.
11.
ZhaoJXZengYYLiuY. Fetal alloantigen is responsible for the expansion of the CD4(+)CD25(+) regulatory T cell pool during pregnancy. J Reprod Immunol. 2007;75(2):71–81.
12.
WhiteHDCrassiKMGivanAL. CD3+ CD8+ CTL activity within the human female reproductive tract: influence of stage of the menstrual cycle and menopause. J Immunol. 1997;158(6):3017–3027.
13.
WiraCRFaheyJVGhoshMPatelMVHickeyDKOchielDO. Review article: sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol. 2010;63(6):544–565.
14.
WiraCRFaheyJVSentmanCLPioliPAShenL. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev. 2005;206(1):306–335.
15.
WiraCRFaheyJV. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS. 2008;22(15):1909–1917.
16.
WHO. World Cancer Report 2014. Lyon: World Health Organization; 2014.
17.
MatzingerP. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
18.
MedawarP. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp Soc Exp Biol. 1953;7:320–338.
19.
BonneyEAMatzingerP. Much IDO about pregnancy. Nat Med. 1998;4(10):1128–1129.
20.
KohlJ. Self, non-self, and danger: a complementary view. Adv Exp Med Biol. 2006;586:71–94.
21.
LaffertyKJGazdaLS. Tolerance: a case of self/not-self discrimination maintained by clonal deletion?Hum Immunol. 1997;52(2):119–126.
22.
MatzingerP. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305.
23.
HaddadJJLandSCTarnow-MordiWOZembalaMKowalczykDLauterbachR. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J Pharmacol Exp Ther. 2002;300(2):559–566.
24.
KimREmiMTanabeKArihiroK. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006;66(11):5527–5536.
25.
SomasundaramRJacobLSwobodaR. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 2002;62(18):5267–5272.
26.
LiyanageUKMooreTTJooHG. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756–2761.
27.
MunnDHMellorAL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117(5):1147–1154.
28.
ZhuBT. Development of selective immune tolerance towards the allogeneic fetus during pregnancy: role of tryptophan catabolites (Review). Int J Mol Med. 2010;25(6):831–835.
29.
KudoYBoydCARSargentILRedmanCWG. Tryptophan degradation by human placental indoleamine 2, 3-dioxygenase regulates lymphocyte proliferation. J Physiol. 2001;535(1):207–215.
30.
LesseyBAYoungSL.The Structure, Function and Evaluation of the Female Reproductive Tract. In StrausJFIIIBarbieriRL, eds. Yen and Jaffe's Reproductive Endocrinology. Vol 7th Ed. Elservier Saunders; 2014: 192–235.
31.
DimitriadisEWhiteCJonesRSalamonsenL. Cytokines, chemokines and growth factors in endometrium related to implantation. Hum Reprod Update. 2005;11(6):613–630.
32.
GiudiceLC. Implantation and endometrial function. In: FauserBCJM, ed Molecular Biology in Reproductive Medicine. New York and London:Parthenon Publishing Group; 1999.
33.
KämmererUvon WolffMMarkertUR. Immunology of human endometrium. Immunobiology. 2004;209(7):569–574.
RussellJHLeyTJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20(1):323–370.
36.
SmythMJThiaKYStreetSE. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000;191(4):661–668.
37.
SmythMJThiaKYTStreetSEAMacGregorDGodfreyDITrapaniJA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192(5):755–760.
38.
StreetSECretneyESmythMJ. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis. Blood. 2001;97(1):192–197.
39.
StreetSETrapaniJAMacGregorDSmythMJ. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J Exp Med. 2002;196(1):129–134.
40.
van den BroekMEKägiDOssendorpF. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184(5):1781–1790.
41.
NaitoYSaitoKShiibaK. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58(16):3491–3494.
42.
HaanenJBaarsAGomezR. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother. 2006;55(4):451–458.
43.
ReichertTEDayRWagnerEMWhitesideTL. Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res. 1998;58(23):5344–5347.
44.
SatoEOlsonSHAhnJ. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102(51):18538–18543.
45.
SträterJHinzUHaselC. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95 L mediated control of minimal residual disease. Gut. 2005;54(5):661–665.
46.
YoshimotoMSakamotoGOhashiY. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer. 1993;72(10):2993–3001.
47.
YasunagaMTabiraYNakanoK. Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann Thorac Surg. 2000;70(5):1634–1640.
48.
GalonJCostesASanchez-CaboF. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
49.
NorianLARodriguezPCO’MaraLA. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res. 2009;69(7):3086–3094.
50.
KusmartsevSNefedovaYYoderDGabrilovichDI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172(2):989–999.
51.
GabrilovichDINagarajS. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–174.
52.
MunnDHSharmaMDBabanB. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-dioxygenase. Immunity. 2005;22(5):633–642.
53.
RodriguezPCZeaAHCulottaKSZabaletaJOchoaJBOchoaAC. Regulation of t cell receptor cd3ζ chain expression byl-arginine. J Biol Chem. 2002;277(24):21123–21129.
54.
RodriguezPCQuicenoDGZabaletaJ. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839–5849.
RodriguezPCHernandezCPMorrowK. L-arginine deprivation regulates cyclin D3 mRNA stability in human T cells by controlling HuR expression. J Immunol. 2010;185(9):5198–5204.
57.
YamamotoSHayaishiO. Tryptophan pyrrolase of rabbit intestine. D- and L-tryptophan-cleaving enzyme or enzymes. J Biol Chem. 1967;242(22):5260–5266.
58.
ShimizuTNomiyamaSHirataFHayaishiO. Indoleamine 2,3-dioxygenase. Purification and some properties. J Biol Chem. 1978;253(13):4700–4706.
59.
KingNJCThomasSR. Molecules in focus: indoleamine 2, 3-dioxygenase. Int J Biochem Cell Biol. 2007;39(12):2167–2172.
60.
LöbSKönigsrainerAZiekerD. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009;58(1):153–157.
61.
TaylorMWFengGS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516–2522.
62.
MellorALMunnDH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4(10):762–774.
63.
FengGSTaylorMW. Interferon gamma-resistant mutants are defective in the induction of indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A. 1989;86(18):7144–7148.
64.
von Bergwelt-BaildonMSPopovASaricT. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood. 2006;108(1):228–237.
WekSAZhuSWekRC. The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol. 1995;15(8):4497–4506.
68.
ZaborskeJMNarasimhanJJiangL. Genome-wide analysis of tRNA charging and activation of the eIF2 kinase Gcn2p. J Biol Chem. 2009;284(37):25254–25267.
69.
FrumentoGRotondoRTonettiMDamonteGBenattiUFerraraGB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002;196(4):459–468.
70.
WeberWPFeder-MengusCChiarugiA. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006;36(2):296–304.
71.
LiuHLiuLLiuKBizargityPHancockWWVisnerGA. Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2, 3-dioxygenase-dependent immune suppression. J Immunol. 2009;183(2):1022–1031.
72.
SharmaMDBabanBChandlerP. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(9):2570–2582.
73.
YanYZhangG-XGranB. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol. 2010;185(10):5953–5961.
74.
MaruyamaTKonkelJEZamarronBFChenW. The molecular mechanisms of Foxp3 gene regulation. Paper presented at: Seminars in immunology, December 2011.
75.
MezrichJDFechnerJHZhangXJohnsonBPBurlinghamWJBradfieldCA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198.
76.
MunnDHZhouMAttwoodJT. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998;281(5380):1191–1193.
77.
BanYChangYDongBKongBQuX. Indoleamine 2,3-dioxygenase levels at the normal and recurrent spontaneous abortion fetal-maternal interface. J Int Med Res. 2013;41(4):1135–1149.
78.
von RangoUKruscheCABeierHMClassen-LinkeI. Indoleamine-dioxygenase is expressed in human decidua at the time maternal tolerance is established. J Reprod Immunol. 2007;74(1-2):34–45.
79.
KudoYBoydCASpyropoulouI. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta. J Reprod Immunol. 2004;61(2):87–98.
80.
HonigARiegerLKappMSutterlinMDietlJKammererU. Indoleamine 2,3-dioxygenase (IDO) expression in invasive extravillous trophoblast supports role of the enzyme for materno-fetal tolerance. J Reprod Immunol. 2004;61(2):79–86.
81.
BreumLRasmussenMHHilstedJFernstromJD. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. Am J Clin Nutr. 2003;77(5):1112–1118.
82.
MunnDHShafizadehEAttwoodJTBondarevIPashineAMellorAL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. The J Exp Med. 1999;189(9):1363–1372.
83.
MullerAHeselerKSchmidtSKSpekkerKMackenzieCRDaubenerW. The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med. 2009;13(6):1125–1135.
84.
SedlmayrPBlaschitzAWintersteigerR. Localization of indoleamine 2, 3-dioxygenase in human female reproductive organs and the placenta. Mol Hum Reprod. 2002;8(4):385–391.
85.
FribergMJenningsRAlsarrajM. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101(2):151–155.
86.
LeeJRDaltonRRMessinaJL. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest. 2003;83(10):1457–1466.
87.
UyttenhoveCPilotteLThéateI. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9(10):1269–1274.
88.
SchroecksnadelKFieglMPrasslKWinklerCDenzHAFuchsD. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol. 2007;133(7):477–485.
89.
BrandacherGPerathonerALadurnerR. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res. 2006;12(4):1144–1151.
90.
OkamotoANikaidoTOchiaiK. Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clinical cancer research. 2005;11:6030–6039.
91.
InoKYoshidaNKajiyamaH. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006;95(11):1555–1561.
92.
PlattenMWickWVan den EyndeBJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 2012;72(21):5435–5440.
93.
CurtiATrabanelliSSalvestriniVBaccaraniMLemoliRM. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009;113(11):2394–2401.
94.
MunnDHSharmaMDHouD. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114(2):280–290.
95.
IshioTGotoSTaharaKToneSKawanoKKitanoS. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2004;19(3):319–326.
96.
KaiSGotoSTaharaKSasakiAKawanoKKitanoS. Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth. J Exp Ther Oncol. 2003;3(6):336–345.
97.
WangDSagaYMizukamiH. Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol. 2012;40(4):929–934.
98.
ShinJHZhangLMurillo-SaucaO. Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2013;110(30):12391–12396.
99.
RiesenbergRWeilerCSpringO. Expression of indoleamine 2, 3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res. 2007;13(23):6993–7002.
100.
ThakerAIRaoMSBishnupuriKS. IDO1 Metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology. 2013;145(2):416–425. e414.
101.
MullerAJDuHadawayJBDonoverPSSutanto-WardEPrendergastGC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Med. 2005;11(3):312–319.
102.
YangHJYenMCLinCC. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med. 2010;235(7):869–876.
103.
HouDYMullerAJSharmaMD. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007;67(2):792–801.
104.
UyttenhoveCPilotteLTheateI. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269–1274.
105.
Van den EyndeBTheateIUyttenhoveCColauDPilotteLStroobantV. Tumoral immune resitance based on tryptophan degradation by indoleamine 2,3-dioxygenase. International Congress Series. Vol. 1304: Elservier; 2007:274–277.
106.
JenkinsonCPGrodyWWCederbaumSD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol. 1996;114(1):107–132.
107.
AktanF. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75(6):639–653.
108.
MorrisSMJrRegulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22(1):87–105.
109.
MunderMEichmannKMoránJMCentenoFSolerGModolellM. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol. 1999;163(7):3771–3777.
110.
BarksdaleARBernardACMaleyME. Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery. 2004;135(5):527–535.
111.
BansalVSyresKMMakarenkovaV. Interactions between fatty acids and arginine metabolism: implications for the design of immune-enhancing diets. JPEN J Parenter Enteral Nutr. 2005;29(1 suppl): S75–S80.
112.
RodriguezPCHernandezCPQuicenoD. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med. 2005;202(7):931–939.
113.
MorrisSMJrKepka-LenhartDChenL-C. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am J Physiol. 1998;275(5): E740–E747.
114.
BernardACFitzpatrickEAMaleyME. Beta adrenoceptor regulation of macrophage arginase activity. Surgery. 2000;127(4):412–418.
115.
BansalVOchoaJB. Arginine availability, arginase, and the immune response. Curr Opin Clin Nutr Metab Care. 2003;6(2):223–228.
KropfPBaudDMarshallSE. Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy. Eur J Immunol. 2007;37(4):935–945.
118.
Vadillo-OrtegaFPerichart-PereraOEspinoS. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011;342: d2901.
119.
MorrisNHEatonBMDekkerG. Nitric oxide, the endothelium, pregnancy and pre-eclampsia. Br J Obstet Gynaecol. 1996;103(1):4–15.
120.
RaberPLThevenotPSierraR. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer. 2014;134(12):2853–2864.
121.
KwonHWuGBazerFWSpencerTE. Developmental changes in polyamine levels and synthesis in the ovine conceptus. Biol Reprod. 2003;69(5):1626–1634.
122.
Ruiz-AlonsoMBlesaDSimónC. The genomics of the human endometrium. Biochim Biophys Acta. 2012;1822(12):1931–1942.
123.
TajimaMHaradaTIshikawaTIwaharaYKubotaT. Augmentation of arginase II expression in the human endometrial epithelium in the secretory phase. J Med Dent Sci. 2012;59(4):75–82.
124.
BronteVZanovelloP. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5(8):641–654.
125.
Suer GokmenSYorukYCakirEYorulmazFGulenS. Arginase and ornithine, as markers in human non-small cell lung carcinoma. Cancer Biochem Biophys. 1999;17(1-2):125–131.
126.
OchoaACZeaAHHernandezCRodriguezPC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2 Pt 2):721s–726s.
127.
KocnaPFricPZavoralMPelechT. Arginase activity determination. A marker of large bowel mucosa proliferation. Eur J Clin Chem Clin Biochem. 1996;34(8):619–623.
128.
PorembskaZLuboinskiGChrzanowskaAMielczarekMMagnuskaJBaranczyk-KuzmaA. Arginase in patients with breast cancer. Clin Chim Acta. 2003;328(1-2):105–111.
129.
PolatMFTaysiSPolatSBoyukABakanE. Elevated serum arginase activity levels in patients with breast cancer. Surg Today. 2003;33(9):655–661.
130.
SevkoAUmanskyV. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J Cancer. 2013;4(1):3.
131.
VissersYLDejongCHLuikingYCFearonKCvon MeyenfeldtMFDeutzNE. Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency?Am J Clin Nutr. 2005;81(5):1142–1146.
132.
KaplanIAydinYBilenYGencFKeleşMSEroğluA. The evaluation of plasma arginine, arginase, and nitric oxide levels in patients with esophageal cancer. Turk J Med Sci. 2012;42(3):403–409.
133.
AsciertoPAScalaSCastelloG. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol. 2005;23(30):7660–7668.
134.
FeunLGMariniAWalkerG. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer. 2012;106(9):1481–1485.
135.
MorrisSMJrRegulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87–105.
136.
DelageBFennellDANicholsonL. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762–2772.
137.
LongYTsaiWBWangpaichitrM. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther. 2013;12(11):2581–2590.
138.
TsaiWBAibaILongY. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012;72(10):2622–2633.
139.
TsaiWBAibaILeeSYFeunLSavarajNKuoMT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther. 2009;8(12):3223–3233.
140.
DillonBJPrietoVGCurleySA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer. 2004;100(4):826–833.
141.
WaltsAEBomalaskiJSInesDOrsulicS. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. J Cancer Res Clin Oncol. 2015;141(8):1363–1369.
142.
BronteVKasicTGriG. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med. 2005;201(8):1257–1268.
143.
IvanenkovYAChufarovaNV. Small-molecule arginase inhibitors. Pharm Pat Anal. 2014;3(1):65–85.
144.
MullerAJMalachowskiWPPrendergastGC. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets. 2005;9(4):831–849.
